



INTRODUCING RicovAI-19: THE ARTIFICIAL INTELLIGENCE FROM ALMAWAVE AT THE SERVICE OF HEALTH CARE IN THE FIGHT AGAINST COVID

Citizens and doctors in the town of Offagna (AN) protagonists of pilot scientific study and clinical experimentation to analyze the patient's clinical parameters in real time

“AI a strategic ally of patients and doctors in fighting the pandemic”
Almawave CEO Valeria Sandei says

Rome, 8 April 2021 - Almawave, a leading Italian company in Artificial Intelligence (AI), natural language analysis and Big Data services, introduces RicovAI-19, a project launched this week in the municipal territory of Offagna (AN), thanks to the collaboration between the Ancona Riuniti Hospital, Polytechnic University of the Marche, ASUR Marche and the companies Vivisol and Aditech. This is a pilot feasibility study (non-pharmacological interventional) and clinical experimentation in which Artificial Intelligence concretely supports patients, doctors and hospitals on multiple levels in the complex challenge of fighting the Covid-19 pandemic and in prospective applicability to the diagnosis and prognosis of various other diseases.

The AI technologies developed for this project from Almawave allows the real-time analysis of multiple clinical parameters in users positive with Covid symptoms (body temperature, blood pressure, oxygen saturation and respiratory rate). It also allows the Clinical Stability indicators to be calculated and the results promptly sent to the doctors. The latter will remotely conduct all the subsequent assessments, make the diagnosis and prescribe any care and initiatives to manage each case. All of this takes place free of charge, thanks to a portable device used with a cell phone and a dedicated app. The instrumentation is made available to patients free of charge, thanks to the investments made by Almawave and the collaboration of the other partners.

The goal of RicovAI-19, in addition to reducing Emergency Room traffic, is to rethink remote medical assistance and the territorial health care model in general.

“Artificial Intelligence is ready to confirm its status as a strategic ally for our lives, even more so in a setting like our current one”, said Valeria Sandei, Almawave Chief Executive Officer. “After years of efforts, research and investments in advanced technologies to apply in the health care area as well, we are pleased to be a fundamental part of concrete pilot clinical experimentation like RicovAI-19. Working side by side with our engineers and a health care professional like

professor Marco Mazzanti, Scientific Director of the Study, allowed us to fine tune an innovative system, capable of perfectly integrating the evolutions of the scientific and technological world with the territorial health care needs. A sensor concretely detects multiple values in the symptomatic patient, such as body temperature, blood pressure and oxygen saturation. These are communicated to a special app. In real time, the Almawave AI engine interprets all the data and information, calculating the clinical stability indicator and making it available to the doctors, who are responsible for the clinical, treatment and assessment actions based on the needs of each individual patient. We are confident that in the near future, this model can be applied in multiple health care areas, providing an increasingly more strategic value at the service of citizens and doctors.”

The project anticipates the participation by Offagna residents in RicovAI-19. Adult citizens, based on the recommendation of their doctor, will be able to receive the instrumentation (Multi-parameter Devices) for independent monitoring - from home - by going to a location made available by the Municipality. Here, they will receive an explanation on how to use the app with relative sending of the results from an initial “test” monitoring to the system for processing by Almawave. This will obviously be the procedure in cases where the clinical condition of the patient does not require different urgent attention.

The initiative has already been granted special authorization by the Ancona Riuniti Hospital Ethics Committee.

“One of the goals of the pilot scientific study”, says Dr. Marco Mazzanti, Scientific Director of RicovAI-19, already on the front line in the London Barts Heart Centre and Ancona Riuniti hospitals and working on other fronts implementing AI Health with Almawave, “is to monitor the appropriateness of hospital access, so that it only takes place when necessary, in addition to obviously understanding how much Artificial Intelligence can be useful in monitoring the health condition of patients.” In fact, according to Dr. Mazzanti, “In the feasibility study, it will be the doctor who supervises the AI application, confirming the data and personally verifying the quality of the predictive indicators provided by the system. The procedure, which creates a relationship between the computer system that supports decisions with the doctor’s supervision, allows for greater accuracy of the treatment.”

“The doctor”, Mazzanti concludes, “is thereby able to simultaneously follow the clinical condition of multiple patients, focusing attention on the most critical. This way, virtuous coordination is launched between the territory, the reference hospital and the doctor, who remains the spearhead at the service of the community. This collaboration is made possibly by the ease of use of the digital applications fine tuned by Almawave so that RicovAI-19 is a useful, reliable and easy-to-use system for the citizen.”

The experimentation will last a total of 6 months, but it will immediately provide useful results for doctors and researchers.



Almawave Profile

Almawave S.p.A. is a leading Italian company in Artificial Intelligence and natural written and spoken language analysis. Almawave has cutting-edge proprietary technologies and applied services to substantiate the potential of AI in the digital evolution of companies and local government. It has an international presence with the companies Almawave do Brasil, Almawave USA and PerVoice, dedicated technological laboratories and more than 220 professionals who are highly competent in enabling technologies and major frameworks - Big Data, Data Science, Machine Learning, AI Architecture and Integration - as well as a profound knowledge of business processes.

Almawave's technological assets, conceived and created as models of natural experience in the interaction between man and machine, allow text and voice to be interpreted in over 30 languages, as well as multichannel interaction, analyzing data and information with a view to enhancing knowledge and automation. The company, part of the Almaviva group, began as Almaviva Consulting S.r.l., taking on the name Almawave in 2010, the year in which it also launched its Brazilian subsidiary (Almawave do Brasil). In 2013, it acquired control of the company PerVoice S.p.A., created as a spin-off of the Bruno Kessler Foundation. In 2017, along with Almaviva and other partners, it was awarded 2 lots of the Consip tender for the public connectivity system. The company can count on more than 100 customers and more than 30 thousand users of its platforms.

Almawave finished the first 9 months of 2020 with proceeds equal to €18 million, up 32.8% compared to the same period the previous year, an Ebitda of €4 million (+17.3%), an operating Free Cash Flow prior to investments of €5.2 million and a generation of cash flow net of investments of €2.3 million. The results fall within a growth trend of the last accounting periods: between 2017 and 2019, proceeds went from €13.9 million to €21.3 million with a compound annual growth rate (CAGR) of 24%. In the same three-year period, the Ebitda increased in line with the turnover.

The strong generation of cash flow, despite the robust investments in Research & Development, is a further testament of solidity and sustainability in the company's growth path.

For information

Almawave Contacts (external Press Office):

Thanai Bernardini, cell. 335.7245418, me@thanai.it

Alessandro Valenti, cell. 348.0090866, alessandro.valenti@thanai.it

Almaviva Group Contacts:

Ilaria De Bernardis, Media Relations Manager, cell. 342.9849109, i.debernardis@almaviva.it

Mariagrazia Scaringella, Media Relations, tel. 06.3993.1, cell. 340.8455510, m.scaringella@almaviva.it

IR Contacts:

Luis Bergter, tel. 06.3993.2947, investor.relations@almawave.it

IR Advisor Contacts:

Mara Di Giorgio, cell. 335.7737417, mara@twin.services

Simona D'Agostino, cell. 335.7729138, simona.dagostino@hear-ir.com

